par Pixmaker | Jan 23, 2025 | Non classé
Eukarÿs and Genethon have announced a strategic partnership to reduce the cost of gene therapy drugs production. By combining Eukarÿs’ innovative disruptive C3P3 technology, which enhances unleashes mRNA synthesis in mammalian cells, with Genethon’s...
par Pixmaker | Déc 10, 2024 | Publication
We are pleased to share that Philippe H. Jais was a featured speaker at the World Vaccine Congress in Boston on November 12, 2024. As a recognized expert in biotechnology and medical innovation, Philippe presented on the topic: « In Vivo Synthesis of Messenger RNA by...
par Pixmaker | Déc 10, 2024 | Corporate
A new study led by Washington University and published in Nature – Vaccines, highlights the use of C3P3 technology in vaccine research targeting rotaviruses. These viruses, which cause severe gastroenteritis, remain a major cause of infant mortality in...
par Pixmaker | Déc 10, 2024 | Award
Eukarys is pleased to announce that it has been awarded Sanofi’s Golden Ticket 2024, which provides one year of free laboratory space at BioLabs France Hôtel-Dieu. We are proud to be the first biomanufacturing technology start-up to receive this prestigious...
par Pixmaker | Déc 1, 2024 | Award
Eukarys is proud to announce a new milestone in its innovation journey with the support of Bpifrance as part of the DeepTech Development program and the France 2030 initiative. This recognition underlines our commitment to revolutionize biomanufacturing with our C3P3®...
